Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies S.A. develops treatment options for food allergies and other immunologic conditions as a late-stage biopharmaceutical company. Company updates center on the proprietary VIASKIN® patch technology, epicutaneous immunotherapy, and the VIASKIN Peanut program for peanut-allergic toddlers and children.
Recurring developments include clinical data from the Phase 3 VITESSE study, annual and quarterly financial results, financing and warrant-related capital actions, leadership and governance changes, share and voting-rights disclosures under French market rules, and market information tied to DBVT American Depositary Shares.
Monthly Update: As of December 31, 2020, the company reported a total of 54,929,187 shares and 54,929,187 voting rights on the NYSE Euronext Paris. The net voting rights total was 54,816,885, accounting for shares without voting rights.
This disclosure adheres to Article 223-16 of the General Regulations of the Autorité des Marchés Financiers, ensuring transparency and compliance in reporting shareholding details.
As of November 30, 2020, the company reported a total of 54,929,187 shares outstanding on the NYSE Euronext Paris. The total number of voting rights associated with these shares is 54,929,187, while the net total of voting rights, accounting for shares without voting rights, stands at 54,815,187. This information complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies announced leadership changes with Dr. Hugh Sampson stepping down as Chief Scientific Officer effective December 1, 2020. He will transition to a role as Scientific Adviser to the CEO, remaining involved with the development of the epicutaneous immunotherapy platform. Dr. Sampson, who has been influential in advancing food allergy treatments, believes this change allows him to refocus on his research at Mount Sinai. DBV’s commitment to the Viaskin technology remains strong as they continue clinical trials aimed at food allergies.
Company Update: As of October 31, 2020, the total number of shares for the Company is 54,927,187, with a total number of voting rights amounting to 54,927,187 (gross) and 54,786,929 (net). This data reflects compliance with the Autorité des Marchés Financiers regulations.
Market: NYSE Euronext Paris | ISIN Code: FR 0010417345
DBV Technologies will present new data on its Viaskin™ Peanut treatment at the ACAAI Annual Scientific Meeting from Nov. 13-15, 2020. Key highlights include four accepted abstracts, with one oral presentation and three poster presentations, detailing the treatment's patient experience, patch adhesion, and prediction of desensitization to peanuts. The event will also feature a symposium on managing food allergies during the COVID-19 pandemic. DBV's ongoing commitment to innovative treatments aims to ease the burden of peanut allergies for patients and families.
DBV Technologies announced its participation in several upcoming virtual investor conferences. CEO Daniel Tassé will host fireside chats at the following:
- Credit Suisse Healthcare Conference: November 11, 2020, at 12:30 PM ET
- Stifel Healthcare Conference: November 16, 2020, at 8:00 AM ET
- Evercore HealthconX: December 1, 2020, at 12:35 PM ET
Webcasts will be available on the company’s website, with replays posted afterward. DBV focuses on developing Viaskin™, an innovative immunotherapy platform for food allergies.
DBV Technologies has announced the validation of its Marketing Authorization Application (MAA) for Viaskin™ Peanut by the European Medicines Agency (EMA). This investigational product aims to treat peanut allergies in children aged 4 to 11 through a non-invasive, daily epicutaneous patch. The EMA will now conduct a review, with an initial set of questions expected within 120 days. This follows a Complete Response Letter from the FDA regarding its Biologics License Application. DBV is engaging the FDA to discuss future regulatory pathways.
DBV Technologies reported a cash position of €189.1 million as of September 30, 2020, down from €225.9 million in June. The company noted a decrease in average monthly cash burn during Q3 2020, with expectations for further reduction through 2021, driven by an ongoing global restructuring plan. DBV anticipates a 40-50% reduction in cash burn compared to the first half of 2020. As of September 30, 2020, there were 54,927,187 outstanding shares and 57,687,615 on a fully diluted basis. The company aims to extend its cash runway to the second half of 2022 to continue developing its Viaskin™ Peanut treatment.
As of September 30, 2020, the company reported a total of 54,927,187 shares outstanding, with a total number of voting rights amounting to 54,927,187 gross and 54,819,687 net. This data is in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. The information is essential for shareholders and potential investors.
The press release provides key information on the total number of shares and voting rights of the Company as of August 31, 2020. As per the report, the total number of shares stands at 54,927,187, while the total gross voting rights amount to 54,927,187. The total net voting rights, after accounting for shares without voting rights, is 54,844,056. This information is in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.